Cargando…
New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents
Decades of basic science and clinical research have led to an increased understanding of the pathophysiology of immune thrombocytopenic purpura (ITP), the processes underlying thrombopoiesis, and the treatment of chronic ITP. Now, new agents are available to treat ITP in a nonimmunosuppressive fashi...
Autores principales: | Metjian, Ara, Abrams, Charles S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802075/ https://www.ncbi.nlm.nih.gov/pubmed/20054440 |
Ejemplares similares
-
Caplacizumab in adult patients with acquired thrombotic
thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020) -
A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists
por: Khan, Meaghan, et al.
Publicado: (2010) -
Balancing Therapy with Thrombopoietin Receptor Agonists and Splenectomy in Refractory Immune Thrombocytopenic Purpura: A Case of Postsplenectomy Thrombocytosis Requiring Plateletpheresis
por: Zimmerman, Jacquelyn, et al.
Publicado: (2016) -
Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report
por: Hoshino, Kouki, et al.
Publicado: (2019) -
Immune thrombocytopenic purpura
por: Zainal, Abir, et al.
Publicado: (2019)